NCT02606305View on ClinicalTrials.gov

Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

264

Participants

Timeline

Start Date

March 2, 2016

Primary Completion Date

March 12, 2021

Study Completion Date

March 12, 2021

Conditions
Epithelial Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Interventions
DRUG

Mirvetuximab soravtansine

DRUG

Bevacizumab

DRUG

Carboplatin

DRUG

Pegylated Liposomal Doxorubicin

DRUG

Pembrolizumab

Trial Locations (12)

3000

Universitaire Ziekenhuizen (UZ) Leuven - Gasthuisberg - Leuvens Kankerinstituut, Leuven

19111

Fox Chase Cancer Center, Philadelphia

28033

MD Anderson, Madrid

43026

The Ohio State University, Hilliard

73104

Peggy and Charles Stephenson Oklahoma Cancer Center, Oklahoma City

Unknown

University of California at Los Angeles, Los Angeles

City of Hope, Reno

Centre Hospitalier de l'universite de Montreal (CHUM), Montreal

McGill University Health Center, Montreal

Hospital Vall D'Hebron, Barcelona

02114

Massachusetts General Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

ImmunoGen, Inc.
All Listed Sponsors
lead

ImmunoGen, Inc.

INDUSTRY

NCT02606305 - Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer | Biotech Hunter | Biotech Hunter